Corbus Pharmaceuticals prices $75M public offering of common stock and warrants

Corbus Pharmaceuticals Holdings, Inc.

Offering of 4,744,231 shares at $13.00/share and 1,025,000 pre-funded warrants at $12.9999 each for ~$75M gross proceeds.
Net proceeds to Corbus expected ~$70.5M; underwriters have 30-day option for additional 865,384 shares.
Proceeds to fund clinical pipeline development and general corporate purposes.
Pre-funded warrants exercisable immediately at $0.0001/share, capped at 9.99% beneficial ownership.
Jefferies leads underwriting; RBC, LifeSci Capital, Mizuho as lead managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.